A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer
This study is designed to evaluate the safety and efficacy of neoadjuvant and adjuvant
atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC). Neoadjuvant
therapy will consist of two 21-day cycles with atezolizumab. Following surgery, adjuvant
therapy will consist of up to 12 months of atezolizumab in participants who demonstrate
clinical benefit with neoadjuvant therapy. All participants who undergo surgery will enter a
surveillance period, which consists of standardized blood sample collection and Chest CT
Scans, for up to 2 years. All participants will be monitored for disease recurrence and
survival for up to 3 years after last dose of study drug.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.